KR20140033426A - 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 - Google Patents
디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 Download PDFInfo
- Publication number
- KR20140033426A KR20140033426A KR1020137033506A KR20137033506A KR20140033426A KR 20140033426 A KR20140033426 A KR 20140033426A KR 1020137033506 A KR1020137033506 A KR 1020137033506A KR 20137033506 A KR20137033506 A KR 20137033506A KR 20140033426 A KR20140033426 A KR 20140033426A
- Authority
- KR
- South Korea
- Prior art keywords
- oxo
- phenyl
- mmol
- alkyl
- acetic acid
- Prior art date
Links
- 0 *C[C@](*)(CCc1c2ccc(C(C=C3)=C*C=C3NC(NI)=O)c1)C2=O Chemical compound *C[C@](*)(CCc1c2ccc(C(C=C3)=C*C=C3NC(NI)=O)c1)C2=O 0.000 description 8
- PPMGPCROFCIZSN-UHFFFAOYSA-N Bc(cc1)ccc1[N+]([O-])=O Chemical compound Bc(cc1)ccc1[N+]([O-])=O PPMGPCROFCIZSN-UHFFFAOYSA-N 0.000 description 1
- DKUAUHFLWURXHI-UHFFFAOYSA-N CC(CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)C1=O Chemical compound CC(CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)C1=O DKUAUHFLWURXHI-UHFFFAOYSA-N 0.000 description 1
- KZPVLORFVRUQMW-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2NC(Nc(cc2F)ccc2F)=O)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2NC(Nc(cc2F)ccc2F)=O)OC1(C)C KZPVLORFVRUQMW-UHFFFAOYSA-N 0.000 description 1
- IYNYLGNEDWSCRH-UHFFFAOYSA-N CCOC(C(C)(C)C(CCc1cc(O)ccc11)C1=O)=O Chemical compound CCOC(C(C)(C)C(CCc1cc(O)ccc11)C1=O)=O IYNYLGNEDWSCRH-UHFFFAOYSA-N 0.000 description 1
- PDDUZGIIFUJJJI-UHFFFAOYSA-N CCOC(CC(CC(F)(F)F)(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1=O)=O Chemical compound CCOC(CC(CC(F)(F)F)(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1=O)=O PDDUZGIIFUJJJI-UHFFFAOYSA-N 0.000 description 1
- VNGOANHNUZFIST-UHFFFAOYSA-N CCOC(CC(CCc1c2)(Cc1ccc2-c(cc1)ccc1N)O)=O Chemical compound CCOC(CC(CCc1c2)(Cc1ccc2-c(cc1)ccc1N)O)=O VNGOANHNUZFIST-UHFFFAOYSA-N 0.000 description 1
- RBCFFRLTGMLRJC-UHFFFAOYSA-N CCOC(CC(CCc1c2)(Cc1ccc2-c(cc1)ccc1NC(Nc1cccc(C(F)(F)F)c1)=O)O)=O Chemical compound CCOC(CC(CCc1c2)(Cc1ccc2-c(cc1)ccc1NC(Nc1cccc(C(F)(F)F)c1)=O)O)=O RBCFFRLTGMLRJC-UHFFFAOYSA-N 0.000 description 1
- BNINGNGBIJXLAG-UHFFFAOYSA-N CCOC(CC(CCc1c2)(Cc1ccc2-c(cc1)ccc1[N+]([O-])=O)O)=O Chemical compound CCOC(CC(CCc1c2)(Cc1ccc2-c(cc1)ccc1[N+]([O-])=O)O)=O BNINGNGBIJXLAG-UHFFFAOYSA-N 0.000 description 1
- RHTHHWWWCJCBLK-UHFFFAOYSA-N CCOC(CC(CCc1cc(-c(cc2)ccc2N)ccc11)C1=O)=O Chemical compound CCOC(CC(CCc1cc(-c(cc2)ccc2N)ccc11)C1=O)=O RHTHHWWWCJCBLK-UHFFFAOYSA-N 0.000 description 1
- IXINJADHLRTPLU-UHFFFAOYSA-N CCOC(CC(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1=O)=O Chemical compound CCOC(CC(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1=O)=O IXINJADHLRTPLU-UHFFFAOYSA-N 0.000 description 1
- JQZQYYIJOQCDHA-UHFFFAOYSA-N CCOC(CCC(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1=O)=O Chemical compound CCOC(CCC(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1=O)=O JQZQYYIJOQCDHA-UHFFFAOYSA-N 0.000 description 1
- ZIJMOGFETZHSDB-MHZLTWQESA-N CC[C@@](CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc(cc2)cc(F)c2F)=O)ccc11)C1=O Chemical compound CC[C@@](CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc(cc2)cc(F)c2F)=O)ccc11)C1=O ZIJMOGFETZHSDB-MHZLTWQESA-N 0.000 description 1
- OPPFFJSOTYTQMK-LJAQVGFWSA-N CC[C@@](CC(OCC)=O)(CCc1cc(-c(cc2)ccc2NC(Nc(cc2)cc(F)c2F)=O)ccc11)C1=O Chemical compound CC[C@@](CC(OCC)=O)(CCc1cc(-c(cc2)ccc2NC(Nc(cc2)cc(F)c2F)=O)ccc11)C1=O OPPFFJSOTYTQMK-LJAQVGFWSA-N 0.000 description 1
- FMQLBIOQSIGGSV-AWEZNQCLSA-N COC(C[C@](CC(F)(F)F)(CCc1cc(O)ccc11)C1=O)=O Chemical compound COC(C[C@](CC(F)(F)F)(CCc1cc(O)ccc11)C1=O)=O FMQLBIOQSIGGSV-AWEZNQCLSA-N 0.000 description 1
- BYHKDUFPSJWJDI-UHFFFAOYSA-N O=C(CCc1c2)Cc1ccc2Br Chemical compound O=C(CCc1c2)Cc1ccc2Br BYHKDUFPSJWJDI-UHFFFAOYSA-N 0.000 description 1
- SOVPQBLIXUFLJZ-UHFFFAOYSA-N O=C(Nc(cc1)ccc1Br)Nc(cc1F)ccc1F Chemical compound O=C(Nc(cc1)ccc1Br)Nc(cc1F)ccc1F SOVPQBLIXUFLJZ-UHFFFAOYSA-N 0.000 description 1
- VSEFQAQGCGZLON-UHFFFAOYSA-N O=C(Nc1cc(Cl)ccc1)Nc(c(F)c1)ccc1-c(cc1)cc(CCC2(C3)COC3=O)c1C2=O Chemical compound O=C(Nc1cc(Cl)ccc1)Nc(c(F)c1)ccc1-c(cc1)cc(CCC2(C3)COC3=O)c1C2=O VSEFQAQGCGZLON-UHFFFAOYSA-N 0.000 description 1
- YBWJVFMNWMLZEN-UHFFFAOYSA-N O=C=Nc(cc1F)ccc1F Chemical compound O=C=Nc(cc1F)ccc1F YBWJVFMNWMLZEN-UHFFFAOYSA-N 0.000 description 1
- OTKTZEZTFCAULO-UHFFFAOYSA-N OC(CC(CC(F)(F)F)(CCc1cc(-c(nc2)cnc2NC(Nc(cc2F)ccc2F)=O)ccc11)C1=O)=O Chemical compound OC(CC(CC(F)(F)F)(CCc1cc(-c(nc2)cnc2NC(Nc(cc2F)ccc2F)=O)ccc11)C1=O)=O OTKTZEZTFCAULO-UHFFFAOYSA-N 0.000 description 1
- UNSIFNYMSKXZPB-UHFFFAOYSA-N OC(CC(CC(F)(F)F)(CCc1cc(O)ccc11)C1=O)=O Chemical compound OC(CC(CC(F)(F)F)(CCc1cc(O)ccc11)C1=O)=O UNSIFNYMSKXZPB-UHFFFAOYSA-N 0.000 description 1
- JKIHKCSKFFHIRV-UHFFFAOYSA-N OC(CC(Cc1cc(Br)ccc11)C1=O)=O Chemical compound OC(CC(Cc1cc(Br)ccc11)C1=O)=O JKIHKCSKFFHIRV-UHFFFAOYSA-N 0.000 description 1
- CNQKDFXIPQEAPX-UHFFFAOYSA-N OC(CN(CCc1cc(-c(cc2)ccc2NC(Nc2cc(C(F)(F)F)ccc2)=O)ccc11)C1=O)=O Chemical compound OC(CN(CCc1cc(-c(cc2)ccc2NC(Nc2cc(C(F)(F)F)ccc2)=O)ccc11)C1=O)=O CNQKDFXIPQEAPX-UHFFFAOYSA-N 0.000 description 1
- RFJBFVKZNKQQSJ-SANMLTNESA-N OC(C[C@](CC(F)(F)F)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(Cl)c2)=O)ccc11)C1=O)=O Chemical compound OC(C[C@](CC(F)(F)F)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(Cl)c2)=O)ccc11)C1=O)=O RFJBFVKZNKQQSJ-SANMLTNESA-N 0.000 description 1
- UNSIFNYMSKXZPB-ZDUSSCGKSA-N OC(C[C@](CC(F)(F)F)(CCc1cc(O)ccc11)C1=O)=O Chemical compound OC(C[C@](CC(F)(F)F)(CCc1cc(O)ccc11)C1=O)=O UNSIFNYMSKXZPB-ZDUSSCGKSA-N 0.000 description 1
- UZFDYBISEDYSCF-UHFFFAOYSA-N OCC(CC(O)=O)(CCc1cc(-c(cc2)cc(F)c2NC(Nc2cc(Cl)ccc2)=O)ccc11)C1=O Chemical compound OCC(CC(O)=O)(CCc1cc(-c(cc2)cc(F)c2NC(Nc2cc(Cl)ccc2)=O)ccc11)C1=O UZFDYBISEDYSCF-UHFFFAOYSA-N 0.000 description 1
- HXQREXMESSPABY-UHFFFAOYSA-N Oc(cc1CCC2(C3)COC3=O)ccc1C2=O Chemical compound Oc(cc1CCC2(C3)COC3=O)ccc1C2=O HXQREXMESSPABY-UHFFFAOYSA-N 0.000 description 1
- YXQGWFQIVJEXBK-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1-c1ccc(CC(CC2)=O)c2c1)=O Chemical compound [O-][N+](c(cc1)ccc1-c1ccc(CC(CC2)=O)c2c1)=O YXQGWFQIVJEXBK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1451/DEL/2011 | 2011-05-20 | ||
IN1451DE2011 | 2011-05-20 | ||
US201161495049P | 2011-06-09 | 2011-06-09 | |
US61/495,049 | 2011-06-09 | ||
PCT/US2012/038520 WO2012162127A1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140033426A true KR20140033426A (ko) | 2014-03-18 |
Family
ID=47217644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137033506A KR20140033426A (ko) | 2011-05-20 | 2012-05-18 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
Country Status (19)
Country | Link |
---|---|
US (1) | US9242929B2 (zh) |
EP (1) | EP2723332B1 (zh) |
JP (1) | JP5893724B2 (zh) |
KR (1) | KR20140033426A (zh) |
CN (1) | CN103687595B (zh) |
AU (1) | AU2012259042B2 (zh) |
CA (1) | CA2836666A1 (zh) |
CO (1) | CO6811853A2 (zh) |
CR (1) | CR20130603A (zh) |
DO (1) | DOP2013000273A (zh) |
EA (1) | EA023239B1 (zh) |
ES (1) | ES2572261T3 (zh) |
IL (1) | IL229487A0 (zh) |
MA (1) | MA35398B1 (zh) |
MX (1) | MX2013013565A (zh) |
PE (1) | PE20140618A1 (zh) |
SG (1) | SG194976A1 (zh) |
WO (1) | WO2012162127A1 (zh) |
ZA (1) | ZA201308569B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015010577A2 (pt) * | 2012-11-09 | 2017-07-11 | Glaxosmithkline Llc | compostos utilizados como inibidores da diacilglicerol aciltransferase |
WO2014081995A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
WO2022026380A1 (en) * | 2020-07-29 | 2022-02-03 | Board Of Regents, The University Of Texas System | Urea inhibitors of micro-rna |
CN111747876B (zh) * | 2020-08-03 | 2023-05-26 | 万华化学集团股份有限公司 | 一种氧化角黄素制备虾青素的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006045209A (ja) * | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
TW200606137A (en) * | 2004-07-02 | 2006-02-16 | Sankyo Co | Urea derivatives |
CA2605300A1 (en) * | 2005-04-19 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity |
PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
GB0625654D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
WO2008099221A1 (en) * | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
JP2008255024A (ja) * | 2007-04-02 | 2008-10-23 | Banyu Pharmaceut Co Ltd | ビアリールアミン誘導体 |
WO2009126861A2 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
CN102471276A (zh) | 2009-08-28 | 2012-05-23 | 第一三共株式会社 | 新型四氢异喹啉化合物 |
JP2011088889A (ja) * | 2009-09-24 | 2011-05-06 | Daiichi Sankyo Co Ltd | 新規テトラヒドロイソキノリン誘導体を含有する医薬 |
CN102781915A (zh) * | 2009-12-31 | 2012-11-14 | 皮拉马尔有限公司 | 二酰甘油酰基转移酶抑制剂 |
US8314120B2 (en) * | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
-
2012
- 2012-05-18 CN CN201280035285.1A patent/CN103687595B/zh not_active Expired - Fee Related
- 2012-05-18 PE PE2013002520A patent/PE20140618A1/es not_active Application Discontinuation
- 2012-05-18 MX MX2013013565A patent/MX2013013565A/es not_active Application Discontinuation
- 2012-05-18 AU AU2012259042A patent/AU2012259042B2/en not_active Ceased
- 2012-05-18 WO PCT/US2012/038520 patent/WO2012162127A1/en active Application Filing
- 2012-05-18 JP JP2014511574A patent/JP5893724B2/ja not_active Expired - Fee Related
- 2012-05-18 CA CA 2836666 patent/CA2836666A1/en not_active Abandoned
- 2012-05-18 SG SG2013084603A patent/SG194976A1/en unknown
- 2012-05-18 EA EA201391724A patent/EA023239B1/ru not_active IP Right Cessation
- 2012-05-18 EP EP12789372.5A patent/EP2723332B1/en active Active
- 2012-05-18 ES ES12789372T patent/ES2572261T3/es active Active
- 2012-05-18 US US14/118,913 patent/US9242929B2/en not_active Expired - Fee Related
- 2012-05-18 KR KR1020137033506A patent/KR20140033426A/ko not_active Application Discontinuation
-
2013
- 2013-11-14 ZA ZA2013/08569A patent/ZA201308569B/en unknown
- 2013-11-18 IL IL229487A patent/IL229487A0/en unknown
- 2013-11-19 CO CO13271927A patent/CO6811853A2/es active IP Right Grant
- 2013-11-20 DO DO2013000273A patent/DOP2013000273A/es unknown
- 2013-11-20 CR CR20130603A patent/CR20130603A/es unknown
- 2013-12-13 MA MA36565A patent/MA35398B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20150307445A1 (en) | 2015-10-29 |
EA201391724A1 (ru) | 2014-04-30 |
ZA201308569B (en) | 2014-07-30 |
US9242929B2 (en) | 2016-01-26 |
CA2836666A1 (en) | 2012-11-29 |
SG194976A1 (en) | 2013-12-30 |
PE20140618A1 (es) | 2014-06-05 |
AU2012259042B2 (en) | 2015-06-11 |
IL229487A0 (en) | 2014-01-30 |
WO2012162127A1 (en) | 2012-11-29 |
CN103687595A (zh) | 2014-03-26 |
EP2723332A4 (en) | 2014-10-15 |
MX2013013565A (es) | 2014-01-08 |
DOP2013000273A (es) | 2014-04-15 |
ES2572261T3 (es) | 2016-05-31 |
MA35398B1 (fr) | 2014-09-01 |
AU2012259042A1 (en) | 2013-04-18 |
CR20130603A (es) | 2014-09-09 |
JP2014525895A (ja) | 2014-10-02 |
CN103687595B (zh) | 2017-05-24 |
EP2723332A1 (en) | 2014-04-30 |
EA023239B1 (ru) | 2016-05-31 |
EP2723332B1 (en) | 2016-03-02 |
CO6811853A2 (es) | 2013-12-16 |
JP5893724B2 (ja) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2922933C (en) | 2,8-diazaspiro[4.5]decane and 3,9-dispiro[5.5]undecane derivates and pharmaceutical compositions thereof useful as tryptophan hydroxylase inhibitors | |
CA2914935A1 (en) | Bicyclic sulfonamide compounds as sodium channel inhibitors | |
TW201739744A (zh) | 治療用化合物 | |
KR20160037199A (ko) | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 | |
JP2011520890A (ja) | オキサゾロベンゾイミダゾール誘導体 | |
US20170081342A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
WO2014155301A1 (en) | Substituted bicyclic compounds as inhibitors of ezh2 | |
KR20140033426A (ko) | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 | |
JP2022527892A (ja) | 小分子pd-1/pd-l1阻害剤、pd-l1抗体との医薬組成物及びその使用 | |
CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
TW201739733A (zh) | 芳基甲醯胺及其用途 | |
US9624174B2 (en) | Compounds as diacylglycerol acyltransferase inhibitors | |
AU2013347843A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
CN116947846A (zh) | 一种并环衍生物及其制备方法和用途 | |
CN115215799A (zh) | 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用 | |
JP2021187859A (ja) | 複素環化合物の医薬用途 | |
WO2024121048A1 (en) | Urea compounds as activators of potassium channels kv7.2/7.3 useful in the treatment of cns and pns disorders | |
CN117003756A (zh) | 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂 | |
WO2014081995A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
TW202342017A (zh) | 用於治療與lpa受體活性相關的病狀的化合物及組合物 | |
JP2024511389A (ja) | キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 | |
NZ617991A (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
NZ617991B2 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITB | Written withdrawal of application |